[1] The International Collaborative Ovarian Neoplasm (ICON) Group. (2002) Paclitaxel plus carbo-platin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet, 360, 505-15.

[2] Sackett, D.L., and Wennberg, J.E. (1997) Choosing the best research design for each question. British Medical Journal, 315, 1636.

[3] Sprangers, M.A.G., Cull, A., Bjordal, K., Groenvold, M., and Aaronson, N.K., for the EORTC Study Group on Quality of Life (1993) The European Organization for Research and Treatment of Cancer approach to quality of life assessment: guidelines for developing questionnaire modules. Quality of Life Research, 2, 287-95.

[4] International Germ Cell Cancer Collaborative Group. (1997) International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. Journal of Clinical Oncology, 15, 594-603.

[5] Stephens, R., and Gibson, D. (1993) The impact of clinical trials on the treatment of lung cancer. Clinical Oncology, 5, 211-19.

[6] Crook, A., Duffy, A., Girling, D.J., Souhami, R.L., and Parmar, M.K.B. (1997) Survey on the treatment of non-small cell lung cancer (NSCLC) in England and Wales. European Respiratory Journal, 10, 1552-8.

[7] Hopwood, P., Harvey, A., Davies, J., Stephens, R.J., Girling, D.J., Gibson, D., and Parmar, M.K.B., on behalf of the Medical Research Council Lung Cancer Working Party and the CHART Steering Committee (1998) Survey of the administration of quality of life (QL) questionnaires in three multicentre randomised trials in cancer. European Journal of Cancer, 34, 49-57.

[8] Sambrook, R.J., and Girling, D.J. (2001) A national survey of the chemotherapy regimens used to treat small cell lung cancer (SCLC) in the United Kingdom. British Journal of Cancer, 84, 1447-52.

[9] Mead, G.M., and Stenning, S.P., for the Medical Research Council Testicular Tumour Working Party (1993) Prognostic factors in metastatic non-seminomatous germ cell tumours: the Medical Research Council studies. European Urology, 23, 196-201.

[10] Reading, J., Hall, R.R., and Parmar, M.K.B. (1995) The application of a prognostic factor analysis for Ta.T1 bladder cancer in routine urological practice. British Journal of Urology, 75, 604-7.

[11] Feld, R., Abratt, R., Graziano, S., Jassem, J., Lacquet, L., Ninane, V., Paesmans, M., Rocmans, P., Schiepers, C., Stahel, R., and Stephens, R. (1997) Pretreatment minimal staging and prognostic factors for non-small cell lung cancer. Lung Cancer, 17(Supplement 1), S3-S10.

[12] Fossa, S.D., Oliver, R.T.D., Stenning, S.P., Horwich, A., Wilkinson, P., Read, G., Mead, G.M., Roberts, J.T., Rustin, G., Cullen, M.H., Kaye, S.B., Harland, S.J., and Cook, P. (1997) Prognostic factors for patients with advanced seminoma treated with platinum-based chemotherapy. European Journal ofCancer, 33, 1380-7.

[13] Stephens, R.J., Bailey, A.J., and Machin, D. (1996) Long-term survival in small cell lung cancer: the case for a standard definition. Lung Cancer, 15, 297-309.

[14] Macbeth, F.R., Wheldon, T.E., Girling, D.J., Stephens, R.J., Machin, D., Bleehen, N.M., Lamont, A., Radstone, D.J., and Reed, N.S., for the Medical Research Council Lung Cancer Working Party (1996) Radiation myelopathy: estimates of risk in 1048 patients in three randomized trials of palliative radiotherapy for non-small cell lung cancer. Clinical Oncology, 8, 176-81.

[15] Parmar, M.K.B., Spiegelhalter, D.J., Freedman, L.S., and the CHART Steering Committee. (1994) The CHART trials: Bayesian design and monitoring in practice. Statistics in Medicine, 13,1297-312.

[16] Fayers, P.M., Ashby, D., and Parmar, M.K.B. (1997) Tutorial in biostatistics: Bayesian data monitoring in clinical trials. Statistics in Medicine, 16, 1413-30.

[17] Freedman, L.S., Parkinson, M.C., Jones, W.G., Oliver, R.T.D., Peckham, M.J., Read, G., Newlands, E.S., and Williams, C.J., on behalf of the Medical Research Council Testicular Tumour Subgroup (Urological Working Party) (1987) Histopathology in the prediction of relapse of patients with stage I testicular teratoma treated by orchidectomy alone. Lancet, ii, 294-8.

[18] Read, G., Stenning, S.P., Cullen, M.H., Parkinson, M.C., Horwich, A., Kaye, S.B., and Cook, P.A. (1992) MRC prospective study of surveillance for stage I testicular teratoma. Journal of Clinical Oncology, 10, 1762-8.

[19] Cullen, M.H., Stenning, S.P., Parkinson, M.C., Fossa, S.D., Kaye, S.B., Horwich, A., Harland, S.J., Williams, M.V., and Jakes, R., for the MRC Testicular Tumour Working Party (1996) Short course adjuvant chemotherapy in high risk stage I NSGCT: an MRC study report. Journal of Clinical Oncology, 14, 1106-13.

[20] MRC Working Party on Testicular Tumours. (1985) Prognostic factors in advanced non-seminomatous germ cell tumours: results of a multicentre study. Lancet, i, 8-11.

[21] Mead, G.M., Stenning, S.P., Parkinson, M.C., Horwich, A., Fossa, S.D., Wilkinson, P.M., Kaye, S.B., Newlands, E.S., and Cook, P.A. (1992) The second MRC study of prognostic factors in NSGCT. Journal of Clinical Oncology, 10, 85-94.

[22] Horwich, A., Sleijfer, D., Fossa, S.D., Kaye, S.B., Oliver, R.T.D., Cullen, M.H., Mead, G.M., de Wit, R., de Mulder, P.H.M., Dearnaley, D.P., Cook, P.A., Sylvester, R.J., and Stenning, S.P. (1997) A randomised trial of bleomycin, etoposide and cisplatin compared to bleomycin, etoposide and carboplatin in good prognosis metastatic non-seminomatous germ cell cancer: a multi-institutional MRC/EORTC trial. Journal of Clinical Oncology, 15, 1844-52.

[23] Kaye, S.B., Mead, G.M., Fossa, S., Cullen, M., de Wit, R., Bodrogi, I., van Groeningen, C., Sylvester, R., Collette, L., Stenning, S., de Prijck, L., Lallemand, E., and de Mulder, P. (1998) BEP vs BOP/VIP for poor prognosis non-seminomatous germ cell tumours: results of an MRC/EORTC randomised trial. Journal of Clinical Oncology, 16, 692-701.

[24] de Wit, R., Roberts, J.T., Wilkinson, P.M., de Mulder, P., H.M., Mead, G.M., Fossa, S.D., Cook, P., de Prijck, L., Stenning, S., and Collette, L. (2001) Equivalence of 3 BEP versus 4 cycles and of the 5 day schedule versus 3 days per cycle in good prognosis germ cell cancer, a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. Journal of Clinical Oncology, 19, 1629-40.

[25] Ovarian Cancer Trialists Group. (1991) Chemotherapy in advanced ovarian cancer - an overview of randomized clinical trials. British Medical Journal, 303, 884-93.

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook

Post a comment